Soleno Therapeutics (SLNO) Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SLNO shares.
View SLNO analyst ratings or view top-rated stocks.

2 equities research analysts have issued 1-year target prices for Soleno Therapeutics' shares. Their SLNO share price forecasts range from $14.00 to $19.00. On average, they predict the company's share price to reach $16.50 in the next twelve months. This suggests a possible upside of 285.5% from the stock's current price.
View analysts price targets for SLNO or view top-rated stocks among Wall Street analysts.

Soleno Therapeutics' stock was trading at $1.98 at the beginning of the year. Since then, SLNO shares have increased by 116.2% and is now trading at $4.28.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our SLNO earnings forecast.

Soleno Therapeutics, Inc. (NASDAQ:SLNO) released its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.70) by $0.11.

Shares of Soleno Therapeutics reverse split on Friday, August 26th 2022. The 1-15 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), OPKO Health (OPK), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Miragen Therapeutics (MGEN), Vaxart (VXRT), Dynavax Technologies (DVAX) and TherapeuticsMD (TXMD).

Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO."

Soleno Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (22.10%), Worth Venture Partners LLC (0.91%), Renaissance Technologies LLC (0.66%) and Geode Capital Management LLC (0.55%). Insiders that own company stock include Bhatnagar Anish, Jack W Schuler, James H Mackaness, Perceptive Advisors Llc and William G Harris.
View institutional ownership trends.

Shares of SLNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SLNO stock can currently be purchased for approximately $4.28.

Soleno Therapeutics (NASDAQ:SLNO) has a market capitalization of $42.76 million. The company earns $-24,070,000.00 in net income (profit) each year or ($3.03) on an earnings per share basis.

Soleno Therapeutics' mailing address is 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065. The official website for the company is www.soleno.life. The company can be reached via phone at (650) 213-8444, via email at ir@soleno.life, or via fax at 650-213-8383.